Monopar Therapeutics (MNPR) Assets Average: 2018-2020
Historic Assets Average for Monopar Therapeutics (MNPR) over the last 3 years, with Sep 2020 value amounting to $15.5 million.
- Monopar Therapeutics' Assets Average rose 189.23% to $15.5 million in Q3 2020 from the same period last year, while for Sep 2020 it was $15.5 million, marking a year-over-year increase of 189.23%. This contributed to the annual value of $10.3 million for FY2019, which is 19.83% up from last year.
- Latest data reveals that Monopar Therapeutics reported Assets Average of $15.5 million as of Q3 2020, which was up 20.74% from $12.8 million recorded in Q2 2020.
- Monopar Therapeutics' 5-year Assets Average high stood at $15.5 million for Q3 2020, and its period low was $5.4 million during Q3 2019.
- In the last 3 years, Monopar Therapeutics' Assets Average had a median value of $8.8 million in 2018 and averaged $9.4 million.
- Per our database at Business Quant, Monopar Therapeutics' Assets Average tumbled by 34.47% in 2019 and then soared by 189.23% in 2020.
- Quarterly analysis of 3 years shows Monopar Therapeutics' Assets Average stood at $7.6 million in 2018, then grew by 21.41% to $9.2 million in 2019, then surged by 189.23% to $15.5 million in 2020.
- Its Assets Average stands at $15.5 million for Q3 2020, versus $12.8 million for Q2 2020 and $13.1 million for Q1 2020.